These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 8243951)

  • 1. [Acute pseudo-angio-cholitic cholestasis during melphalan therapy].
    Barrioz T; Roblot P; Silvain C; Touchard G; Becq-Giraudon B
    Gastroenterol Clin Biol; 1993; 17(6-7):518-9. PubMed ID: 8243951
    [No Abstract]   [Full Text] [Related]  

  • 2. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
    Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M
    Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response of primary hepatic amyloidosis to melphalan and prednisone: a case report and review of the literature.
    Gertz MA; Kyle RA
    Mayo Clin Proc; 1986 Mar; 61(3):218-23. PubMed ID: 3945122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary amyloidosis with unusual bone involvement: reversibility with melphalan, prednisone, and colchicine.
    Schattner A; Varon D; Green L; Hurwitz N; Bentwich Z
    Am J Med; 1989 Mar; 86(3):347-8. PubMed ID: 2919619
    [No Abstract]   [Full Text] [Related]  

  • 5. [Obstructive cholangitis in baby rats, pregnant rats and their litters after medication with 1-naphthyl-isothiocyanate].
    Leinweber B; Rotter S
    Acta Hepatogastroenterol (Stuttg); 1972; 19(4):241-50. PubMed ID: 4677024
    [No Abstract]   [Full Text] [Related]  

  • 6. Primary amyloidosis and acute leukemia associated with melphalan therapy.
    Kyle RA; Pierre RV; Bayrd ED
    Blood; 1974 Sep; 44(3):333-7. PubMed ID: 4527938
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-term risk of myelodysplasia in melphalan-treated patients with immunoglobulin light-chain amyloidosis.
    Gertz MA; Lacy MQ; Lust JA; Greipp PR; Witzig TE; Kyle RA
    Haematologica; 2008 Sep; 93(9):1402-6. PubMed ID: 18641023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Objective response in amyloidosis treated with intermittent chemotherapy.
    Farhangi M; Thakur VM; Durham JB
    South Med J; 1984 Jun; 77(6):775-7. PubMed ID: 6729558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An unusual presentation of primary amyloidosis.
    Dursun M; Ayyildiz O; Yilmaz S; Bilici A
    Saudi Med J; 2004 Oct; 25(10):1478-81. PubMed ID: 15494827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Primary amyloidosis preceded by chronic polyarthritis and melphalan treatment].
    Suzuki A; Adachi T; Akizuki M; Abe T; Homma M
    Ryumachi; 1975 Mar; 15(1):83-91. PubMed ID: 1129656
    [No Abstract]   [Full Text] [Related]  

  • 11. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis.
    Leung N; Dispenzieri A; Fervenza FC; Lacy MQ; Villicana R; Cavalcante JL; Gertz MA
    Am J Kidney Dis; 2005 Aug; 46(2):270-7. PubMed ID: 16112045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis.
    Perfetti V; Siena S; Palladini G; Bregni M; Di Nicola M; Obici L; Magni M; Brunetti L; Gianni AM; Merlini G
    Haematologica; 2006 Dec; 91(12):1635-43. PubMed ID: 17145600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical images: Skeletal muscle pseudo-hypertrophy in myeloma-associated amyloidosis.
    Lawson TM; Bevan MA; Williams BD
    Arthritis Rheum; 2002 Aug; 46(8):2251. PubMed ID: 12209535
    [No Abstract]   [Full Text] [Related]  

  • 14. An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis.
    Sanchorawala V; Seldin DC
    Amyloid; 2007 Dec; 14(4):261-9. PubMed ID: 17968685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Destructive bone lesion in primary amyloidosis.
    Venkatachalam S; Balakrishnan C; Mangat G; Deshpande RB; Chinoy R; Joshi VR
    J Assoc Physicians India; 1996 May; 44(5):351-3. PubMed ID: 9282593
    [No Abstract]   [Full Text] [Related]  

  • 16. Amyloidosis-a deadly disease.
    Murphy KE
    Am J Nurs; 1980 Jul; 80(7):1336-8. PubMed ID: 6901584
    [No Abstract]   [Full Text] [Related]  

  • 17. [Systemic ALlambda amyloidosis associated with vascular fragility].
    Laimer M; Kaindl K; Emberger M; Hawranek T; Lanschützer CM; Bauer JW; Linke RP; Mlineritsch B; Hintner H
    J Dtsch Dermatol Ges; 2004 Nov; 2(11):934-9. PubMed ID: 16281613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Current status of the therapy of plasmacytomas (treatment with melphalan)].
    Maroncelli P; Pratesi G; Casalino C; Barbatano L
    Recenti Prog Med; 1968 Sep; 45(3):LI-LXVI. PubMed ID: 4192432
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide.
    Palladini G; Russo P; Lavatelli F; Nuvolone M; Albertini R; Bosoni T; Perfetti V; Obici L; Perlini S; Moratti R; Merlini G
    Ann Hematol; 2009 Apr; 88(4):347-50. PubMed ID: 18779964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis.
    Sanchorawala V; Wright DG; Quillen K; Finn KT; Dember LM; Berk JL; Doros G; Fisher C; Skinner M; Seldin DC
    Bone Marrow Transplant; 2007 Sep; 40(6):557-62. PubMed ID: 17589534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.